Pharmacological inhibition of the CaSR has recently been proposed as a new and effective therapeutic strategy for the treatment of asthma, given the putative pro-inflammatory role that the CaSR seems to play in the lungs (Yarova et al., 2015; Corrigan, 2020; Yarova et al., 2021). The gene discussed is CASR; the disease is asthma.